Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azetukalner - Xenon Pharmaceuticals

Next Previous
X
Search
Drug Profile

Azetukalner - Xenon Pharmaceuticals

Alternative Names: 1OP 2198; Encukalner; VRX 621698; XEN-1101; XPF-008

Latest Information Update: 11 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bausch Health Companies
  • Developer Icahn School of Medicine at Mount Sinai; Xenon Pharmaceuticals
  • Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action KCNQ potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Partial epilepsies; Tonic-clonic epilepsy
  • Phase II Major depressive disorder
  • No development reported Epilepsy

Most Recent Events

  • 09 Sep 2024 Efficacy data from a phase III X-TOLE4 trial for Partial epilepsies (In adults, In the elderly) (PO) released by Xenon Pharmaceuticals
  • 08 Aug 2024 Xenon Pharmaceuticals announces intention to submit NDA to US FDA for Epilepsy
  • 09 May 2024 Xenon Pharmaceuticals announces a successful “end-of-Phase 2” interactions with FDA in Major depressive disorder

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top